This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: University of Alberta. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Shaun McKinnie: Innovator in Cardiovascular Research
Introduction
Shaun McKinnie is a prominent inventor based in Edmonton, Canada. He has made significant contributions to the field of cardiovascular research through his innovative work on apelin peptides. With a total of 2 patents, McKinnie is recognized for his advancements in medical science.
Latest Patents
McKinnie's latest patents focus on modified apelin polypeptides that exhibit increased stability against kallikrein, NEP, and ACE2 degradation. These polypeptides also demonstrate enhanced potency compared to the native apelin-13 and apelin-17 polypeptides. The embodiments of these patents disclose methods for utilizing these polypeptides in the treatment of cardiovascular disorders.
Career Highlights
McKinnie is affiliated with the University of Alberta, where he conducts his research and development. His work has garnered attention for its potential impact on treating cardiovascular diseases, showcasing his commitment to advancing medical knowledge and therapeutic options.
Collaborations
Some of McKinnie's notable coworkers include John C. Vederas and Conrad Fischer. Their collaborative efforts contribute to the innovative research environment at the University of Alberta.
Conclusion
Shaun McKinnie is a dedicated inventor whose work on apelin peptides holds promise for improving cardiovascular treatments. His contributions to the field exemplify the importance of innovation in medical research.